Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo adds cherry-flavored cetirizine

This article was originally published in The Tan Sheet

Executive Summary

FDA approves the private labeler's application to manufacture and market Cetirizine Cherry Syrup, 1 mg/mL - equivalent to Johnson & Johnson/McNeil's Zyrtec Children's Allergy Syrup. Perrigo's store-brand antihistamine will begin shipping to retailers by September, joining its current grape-flavored cetirizine syrup, Perrigo said July 26. The FDA approval is a good sign for Perrigo, as the application originated from the firm's Allegan, Mich., plant that elicited a warning letter in April due to quality system failings, Collins Stewart analyst Louise Chen said in a same-day note (1"The Tan Sheet" June 21, 2010). "We think that the FDA would not have approved a product out of Michigan if the agency felt there were substantive manufacturing issues at the facility," Chen wrote

You may also be interested in...



Perrigo Targets October For Quality System Corrections, FDA Re-Inspection

Perrigo wants FDA to re-inspect its Allegan, Mich., manufacturing plant in October, when the private labeler intends to have corrected its quality system failings that elicited a warning letter in April

Biogen’s RoActemra Biosimilar Begins EU Approvals Process

The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.

FDA To Pilot Biosimilar Regulatory Science Program

As part of BsUFA III, the FDA has announced that it will be commencing its regulatory science research program, which will focus on advancing the development of interchangeable products and biosimilars.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel